The Tp-e interval, and Tp-e/QT Tp-e/QTc ratios were significantly prolonged in patients with wild-type ATTR-CM compared to healthy people. Electrocardiographic (ECG) parameters are prolonged in ...

Inebilizumab-cdon (Uplizna ®) has received US Food and Drug Administration (FDA) approval for the treatment of adults with generalized myasthenia gravis (MG) with antibodies against the acetylcholine ...

More than half (56.3%) of the patients with PBC treated with seladelpar as a second-line therapy achieved a biochemical response. The efficacy of seladelpar as a second-line therapy in patients with ...

The recommendations were based on the available evidence, its certainty, and key judgments using the Grading of Recommendations Assessment, Development and Evaluation framework. New guidelines ...

Biochemical response rates were sustained through week 182 in patients with PBC treated with elafibranor, and the proportion of patients with normal alkaline phosphatase levels remained consistent.

The revisions include the addition of a boxed warning that describes the risk of serious hepatic injury and acute liver failure as well as possible fatal outcomes and the limitation of the use of the ...

A pattern recognition approach takes into account factors like disease progression rate, whether the disease symptoms are symmetrical or asymmetrical, whether they are predominantly distal or proximal ...

The researchers reported that Scheuer stage score increased significantly with histological stage and GLOBE score. The GLOBE score of patients with primary biliary cholangitis (PBC) before treatment ...

Obesity intervention programs may be necessary to prevent joint function deterioration among patients with hemophilia. Obesity prevalence among patients with hemophilia continues to rise as it does in ...

Professor Aya Abrahamov and two Palestinian women with Gaucher disease share a light moment at Shaare Zedek Medical Center in Jerusalem, Israel (Photo by Ari Zimran) Shaare Zedek’s Gaucher unit is the ...

The overall response rate of transfusion-dependent patients was 56% while that of transfusion-independent patients was 46%. Momelotinib treatment leads to clear clinical benefits in patients with ...

Emerging therapies such as bezuclastinib and elenestinib show promise in improving disease control with potentially fewer toxicities. Other novel strategies, such as immune-based therapies, are under ...